Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies

H Li, YF Luo, BJ Williams, TS Blackwell… - International Journal of …, 2012 - Elsevier
Pseudomonas aeruginosa (P. aeruginosa) is a common pathogen isolated from patients
with nosocomial infections. Due to its intrinsic and acquired antimicrobial resistance, limited …

MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of …

C Bretonnière, A Maitte, J Caillon, G Potel… - The Journal of …, 2016 - nature.com
This study aimed to compare the susceptibility to carbapenems (imipenem, meropenem and
doripenem) of clinical strains of Pseudomonas aeruginosa. It also studied whether …

[HTML][HTML] Comparison of in vitro activity of doripenem versus old carbapenems against Pseudomonas aeruginosa clinical isolates from both CF and burn patients

Z Hojabri, MA Rezaee, MR Nahaei… - Advanced …, 2013 - ncbi.nlm.nih.gov
Purpose: The antimicrobial activity of doripenem in comparison of imipenem, meropenem
and ertapenem among Pseudomonas aeruginosa isolated from burn and Cystic Fibrosis …

In Vitro Activity Studies of Doripenem and Two Other Carbapenems Tested Against Pseudomonas aeruginosa and Other Non-Fermentative Bacilli

A De Fera, S Zummo, MT Sarro - Journal of Chemotherapy, 2011 - Taylor & Francis
Over the past decade, an increasing prevalence of infections caused by non-fermenting
Gram-negative bacteria has been reported in many countries. Among these bacteria …

[PDF][PDF] In vitro efficacy of doripenem against Pseudomonas aeruginosa and Acinetobacter baumannii by E-test

M Gilani, T Munir, M Latif, S Rehman, M Ansari… - J Coll Physicians Surg …, 2015 - jcpsp.pk
Objective: To assess the in vitro efficacy of doripenem against Pseudomonas aeruginosa
and Acinetobacter baumannii using Epsilometer strips. Study Design: Cross-sectional study …

Caracterización de los mecanismos de resistencia de aislamientos clínicos de Pseudomonas aeruginosa no sensibles a carbapenems y factores de riesgo asociados …

M Iñigo - 2013 - dadun.unav.edu
En primer lugar, al Dr. Leiva, porque por su “culpa”, o más bien gracias él, me encuentro en
el mundo de la Microbiología, porque siendo su alumna en la Universidad supo …

[PDF][PDF] In-Vitro Activity of Doripenem vs. Imipenem & Meropenem against Clinical Isolates of Pseudomonas and Other Oxidase-Positive Gram-Negative Bacilli

P Singh, R Misra - academia.edu
Background & objectives: Doripenem is approved by United States Food and Drug
Administration (US FDA) for the treatment of complicated urinary tract infections (cUTI) …

Doripenem

BA Rogers - Kucers' The Use of Antibiotics, 2017 - taylorfrancis.com
Doripenem (formerly S-4661),(4R, 5S, 6S)-3-{[(3S, 5S)-5-(sulfamoyla-minomethyl)-pyrrolidin-
3-yl] thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo (3.2. 0) hept-2-ene-2 …

[HTML][HTML] Современные взгляды на применение дорипенема в клинической практике

ОУ Стецюк, ИВ Андреева, РС Козлов - Фарматека, 2017 - pharmateca.ru
Повсеместное появление и стремительное распространение нозокомиальных
грамотрицательных возбудителей с множественной резистентностью к …

MODERN VIEWS ON THE USE OF DORIPENEM IN CLINICAL PRACTICE

OU Stetsyuk, IV Andreeva, RS Kozlov - Pharmateca, 2017 - innoscience.ru
The ubiquitous appearance and rapid spread of nosocomial gram-negative pathogens with
multiple resistance to antimicrobial agents is an extremely alarming trend throughout the …